[go: up one dir, main page]

JP2010150288A - スタチン及びガンマーオリザノールを含有する医薬組成物 - Google Patents

スタチン及びガンマーオリザノールを含有する医薬組成物 Download PDF

Info

Publication number
JP2010150288A
JP2010150288A JP2010067405A JP2010067405A JP2010150288A JP 2010150288 A JP2010150288 A JP 2010150288A JP 2010067405 A JP2010067405 A JP 2010067405A JP 2010067405 A JP2010067405 A JP 2010067405A JP 2010150288 A JP2010150288 A JP 2010150288A
Authority
JP
Japan
Prior art keywords
nitric oxide
blood
oryzanol
gamma
vascular endothelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010067405A
Other languages
English (en)
Japanese (ja)
Inventor
Tatsuhito Kondo
達仁 近藤
Ikuo Takagi
郁夫 高木
Masato Nakayama
正人 中山
Yasuhiro Torizumi
保博 鳥住
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Daiichi Sankyo Healthcare Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Daiichi Sankyo Healthcare Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd, Daiichi Sankyo Healthcare Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to JP2010067405A priority Critical patent/JP2010150288A/ja
Publication of JP2010150288A publication Critical patent/JP2010150288A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010067405A 2002-08-02 2010-03-24 スタチン及びガンマーオリザノールを含有する医薬組成物 Pending JP2010150288A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010067405A JP2010150288A (ja) 2002-08-02 2010-03-24 スタチン及びガンマーオリザノールを含有する医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002225979 2002-08-02
JP2002260719 2002-09-06
JP2010067405A JP2010150288A (ja) 2002-08-02 2010-03-24 スタチン及びガンマーオリザノールを含有する医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003279533A Division JP4607436B2 (ja) 2002-08-02 2003-07-25 ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物

Publications (1)

Publication Number Publication Date
JP2010150288A true JP2010150288A (ja) 2010-07-08

Family

ID=31497621

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010067405A Pending JP2010150288A (ja) 2002-08-02 2010-03-24 スタチン及びガンマーオリザノールを含有する医薬組成物

Country Status (5)

Country Link
JP (1) JP2010150288A (zh)
AU (1) AU2003252358A1 (zh)
CA (1) CA2494801A1 (zh)
TW (1) TW200409635A (zh)
WO (1) WO2004012740A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230149403A (ko) * 2022-04-20 2023-10-27 목포대학교산학협력단 감마-오리자놀을 포함하는 판막증 예방 또는 치료용 조성물

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12239644B2 (en) 2018-11-02 2025-03-04 Kyungpook National University Industry-Academic Cooperation Foundation Composition for prevention or treatment of macular degeneration

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54135740A (en) * 1978-04-13 1979-10-22 Otsuka Nobuhiro Method of dissolving oryznol to greases or their products
JP2001511444A (ja) * 1997-07-31 2001-08-14 コス ファーマスーティカルズ、インコーポレイテッド ＨＭＧ−ＣｏＡ還元酵素阻害剤とニコチン酸化合物との組み合わせ、及び夜に１日１回高脂質血症を治療する方法
JP2001224309A (ja) * 2000-02-10 2001-08-21 Nisshin Oil Mills Ltd:The 血中脂質改善機能を有する食用油脂
WO2002034261A1 (en) * 2000-10-23 2002-05-02 Sankyo Company, Limited Compositions for improving lipids in blood

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038694A1 (en) * 1996-04-17 1997-10-23 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54135740A (en) * 1978-04-13 1979-10-22 Otsuka Nobuhiro Method of dissolving oryznol to greases or their products
JP2001511444A (ja) * 1997-07-31 2001-08-14 コス ファーマスーティカルズ、インコーポレイテッド ＨＭＧ−ＣｏＡ還元酵素阻害剤とニコチン酸化合物との組み合わせ、及び夜に１日１回高脂質血症を治療する方法
JP2001224309A (ja) * 2000-02-10 2001-08-21 Nisshin Oil Mills Ltd:The 血中脂質改善機能を有する食用油脂
WO2002034261A1 (en) * 2000-10-23 2002-05-02 Sankyo Company, Limited Compositions for improving lipids in blood

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012039468; 斉藤一郎: 治療 Ｖｏｌ．　８０（増刊）, 1998, ｐ．　２７４（４７４）-２７５（４７５） *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230149403A (ko) * 2022-04-20 2023-10-27 목포대학교산학협력단 감마-오리자놀을 포함하는 판막증 예방 또는 치료용 조성물
KR102741077B1 (ko) * 2022-04-20 2024-12-10 국립목포대학교산학협력단 감마-오리자놀을 포함하는 판막증 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
WO2004012740A1 (ja) 2004-02-12
CA2494801A1 (en) 2004-02-12
TW200409635A (en) 2004-06-16
AU2003252358A1 (en) 2004-02-23
HK1077230A1 (zh) 2006-02-10

Similar Documents

Publication Publication Date Title
JP2010077162A (ja) 血中ホモシステイン低下のための医薬組成物
US20150272944A1 (en) Novel triglyceride reducing agent
JP4287750B2 (ja) 糸球体疾患治療剤
US20050187204A1 (en) Medicinal composition for lowering blood lipid level
JP4607436B2 (ja) ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物
JP2010150288A (ja) スタチン及びガンマーオリザノールを含有する医薬組成物
US20080070938A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocysteine
US20050182036A1 (en) Medicinal composition containing an HMG-CoA reductase inhibitor
JP4611622B2 (ja) 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
JP4454985B2 (ja) 血液脂質を低下させるための医薬組成物
JP2003503342A (ja) ＭＴＰ阻害剤とＨＭＧ−ＣｏＡ還元酵素阻害剤との組み合わせ並びに薬剤におけるその使用
CN100415235C (zh) 含有HMG-CoA还原酶抑制剂的药物组合物
JP4949661B2 (ja) ＨＭＧ−ＣｏＡリダクターゼ阻害剤とグルタチオンを含有する医薬組成物
HK1077230B (zh) 含有hmg-coa还原酶抑制剂的药物组合物
EP1621210A1 (en) Adiponectin production enhancer
CA2494916A1 (en) Medicinal composition for lowering blood lipid level
JP2002145774A (ja) 医薬組成物
HK1078279A (zh) 降低血脂的药物组合物
HK1077232B (zh) 用於改善血液中脂质或降低血液中高半胱氨酸的药物组合物
HK1111632B (zh) 新颖甘油三酸酯还原剂

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120730

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121024